Trinity Biotech plc (TRIB)
- Previous Close
1.8500 - Open
1.8320 - Bid --
- Ask --
- Day's Range
1.8300 - 1.9130 - 52 Week Range
1.7900 - 5.5000 - Volume
11,194 - Avg. Volume
98,604 - Market Cap (intraday)
13.984M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-4.9600 - Earnings Date Apr 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 5, 2015
- 1y Target Est
--
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
www.trinitybiotech.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TRIB
Performance Overview: TRIB
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRIB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRIB
Valuation Measures
Market Cap
13.98M
Enterprise Value
74.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.20
Price/Book (mrq)
--
Enterprise Value/Revenue
1.05
Enterprise Value/EBITDA
-2.84
Financial Highlights
Profitability and Income Statement
Profit Margin
-42.26%
Return on Assets (ttm)
-13.15%
Return on Equity (ttm)
--
Revenue (ttm)
56.83M
Net Income Avi to Common (ttm)
-36.87M
Diluted EPS (ttm)
-4.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
3.69M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.02M